Clinical trials: Large Bowel Cancer
Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8
Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment
This research trial studies the financial burden in patients with stage I-III colon or rectal cancer who are undergoing treatment.
- Conditions
- Stage I Colon Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Rectal Cancer AJCC v8
- Trial name
- NCT03516942
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- 716 sites in United States
- Volunteers
- 565 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Colorectal Cancer
Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine if panitumumab, in combination with irinotecan, leucovorin, and 5-fluorouracil (5-FU) is safe and efficacious in patients with metastatic colorectal cancer.
- Trial name
- NCT00111761
- Testing
- Irinotecan, Panitumumab, 5-Fluorouracil
- Volunteers
- 43 people
- Sponsor
- Amgen
Colon Polyps
Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.
The effectiveness of colonoscopy in reducing colorectal cancer mortality relies on the detection and removal of neoplastic polyps.
- Trial name
- NCT01936948
- Testing
- Clip closure
- Where
- United States
- Volunteers
- 928 people
- Sponsor
- White River Junction Veterans Affairs Medical Center
Colorectal Cancer
Text Messaging to Improve Adherence To Repeat Colonoscopy In a Veterans Affairs (VA) Hospital
Colorectal cancer is a common but preventable condition, and increasing colorectal cancer screening is one of the most impactful public health contributions in the field of gastroenterology.
- Trial name
- NCT06185374
- Testing
- Text Message Instructions/Motivation
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Stage IV Colorectal Cancer
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
This protocol is a phase I/II, study of ascorbic acid (AA) infusions combined with treatment with irinotecan versus treatment with irinotecan alone in patients with recurrent or advanced colorectal cancer who have failed at least…
- Trial name
- NCT01550510
- Testing
- Ascorbic Acid, Irinotecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Thomas Jefferson University
Colon Carcinoma, Dysplasia in Crohn Disease
Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia
This pilot, randomized phase I/II trial studies how well inositol works in preventing colorectal cancer in patients with abnormal cells (dysplasia) associated with inflammation of the colon (colitis).
- Conditions
- Colon Carcinoma, Dysplasia in Crohn Disease, Low Grade Dysplasia in Ulcerative Colitis, Rectal Carcinoma
- Trial name
- NCT01111292
- Testing
- Inositol
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- National Cancer Institute (NCI)
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
This 2 arm study will compare the pharmacokinetics and safety of Avastin at steady state under 2 different dosing regimens, in combination with XELOX (oxaliplatin + Xeloda) or FOLFOX-4 (oxaliplatin, leucovorin and…
- Trial name
- NCT00349336
- Testing
- bevacizumab [Avastin], XELOX, FOLFOX-4
- Where
- 7 sites in Australia, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
This is an open-label, prospective, randomized, multicenter phase II trial that will evaluate the efficacy and safety of intermittent addition of cetuximab to a FOLFIRI-based first line therapy to patients with RAS (Rat…
- Trial name
- NCT04554836
- Testing
- Cetuximab, FOLFIRI
- Where
- 4 sites in Germany
- Volunteers
- 6 people
- Sponsor
- TheraOp
Colorectal Cancer
Adjuvant Low Dose Aspirin in Colorectal Cancer
ALASCCA is a randomized, parallel group, double blind, multicenter, placebo-controlled, biomarker-based study of adjuvant treatment with low dose aspirin in patients with colorectal cancer.
- Trial name
- ALASCCA (NCT02647099)
- Testing
- Acetylsalicylic acid
- Where
- 32 sites in Denmark, Finland and 2 more
- Volunteers
- 626 people
- Sponsor
- Anna Martling
Metastatic Colorectal Cancer
Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
This study will compare the safety and efficacy of dalotuzumab (MK-0646) in combination with cetuximab and irinotecan in treating participants with wild type KRAS (wtKRAS) metastatic colorectal cancer (CRC) compared to cetuximab…
- Trial name
- NCT00614393
- Testing
- dalotuzumab, irinotecan hydrochloride, cetuximab
- Volunteers
- 558 people
- Sponsor
- Merck Sharp & Dohme LLC
MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer
Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T cells) is effective (anti-tumor activity) and safe in three different patient populations. These include: 1.
- Conditions
- MSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers
- Trial name
- NCT01876511
- Testing
- MK-3475
- Where
- 7 sites in United States
- Volunteers
- 113 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colon Cancer
Engaging Patients in Colon Cancer Screening Decisions During COVID-19
The goal of the study is to examine whether a shared decision making intervention improves decision making about colon cancer screening for patients who had their colonoscopy delayed or postponed due to the COVID pandemic.
- Trial name
- NCT04548531
- Testing
- Shared Decision Making
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Massachusetts General Hospital
Colorectal Cancer
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib
Regorafenib is approved in the treatment for metastatic colorectal cancer patients who have been progressed after standard therapies, however, there has not been a predictive biomarker.
- Trial name
- NCT02175095
- Testing
- Regorafenib, [18F]FLT-PET, [18F]FDG-PET
- Where
- South Korea
- Volunteers
- 68 people
- Sponsor
- Asan Medical Center
Colorectal Neoplasms
Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
This national, multicenter, open-label phase 2 study without any control arm aims to evaluate the activity of cetuximab monotherapy in the treatment of refractory colorectal cancer in subjects with K-RAS mutated and FcγRIIa…
- Trial name
- MUTEX (NCT01450319)
- Testing
- Cetuximab
- Where
- 9 sites in Spain
- Volunteers
- 73 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Carcinoma, Gastric Adenocarcinoma
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
This trial studies tucatinib to find out if it is safe when given with trastuzumab and other anti-cancer drugs (pembrolizumab, FOLFOX, and CAPOX).
- Conditions
- Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT04430738
- Testing
- tucatinib, trastuzumab, oxaliplatin
- Where
- 27 sites in United States, Japan
- Volunteers
- 40 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma
A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
This phase II trial studies how well capecitabine and celecoxib with or without radiation therapy works in treating patients with colorectal cancer that is newly diagnosed or has been previously treated with fluorouracil, and has…
- Conditions
- Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
- Trial name
- ADAPT (NCT01729923)
- Testing
- Capecitabine, Celecoxib, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
Colorectal Cancer
Ancillary Study of Methylation Biomarkers in a Randomized Controlled Trial of a Personalized Prevention of Colorectal Cancer
Based on the magnesium tolerance test (MTT, "gold standard" for assessing magnesium (Mg) status), it was found that over 50% of participants in the US exhibited Mg deficiency.
- Trial name
- NCT04196803
- Testing
- Magnesium glycinate
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Colorectal Cancer
A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer
People with colorectal cancer that cannot be cured by surgery are being asked to participate in this study. The purpose of this study is to test the efficacy (effectiveness) of a new combination of drugs, ABT-888 and temozolomide…
- Trial name
- NCT01051596
- Testing
- Temozolomide, ABT-888
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Georgetown University
Advanced Colorectal Cancer
Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer
The purpose of this study is to evaluate progression free survival primarily. The secondary objectives are to evaluate the antitumor activity, as assessed by objective tumor response, duration of clinical benefit, overall…
- Trial name
- NCT00824161
- Testing
- TAS-109
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.